吉非替尼治疗晚期非小细胞肺癌疗效与T细胞亚群变化分析

Analysis the effects of Gefitinib in patients with advanced non-small cell lung cancer and the Variations of T lymphocyte subsets

目的探讨吉非替尼治疗晚期非小细胞肺癌(NSCLC)疗效与毒副反应以及患者治疗前后T细胞亚群的变化特点。方法对经组织或细胞病理学证实的60例晚期NSCLC患者给予口服吉非替尼250 mg/d。采集患者治疗前后外周血标本,应用流式细胞术检测CD3+、CD4+、CD8+T细胞亚群的表达。结果 60例患者部分缓解21例,稳定23例,进展16例,疾病控制率为73.3%。与药物相关的不良反应为皮疹、皮肤干燥、腹泻、恶心和肝功能异常。治疗前后CD3+、CD4+、CD8+T细胞亚群表达差异无统计学意义(P>0.05)。结论吉非替尼治疗晚期非小细胞肺癌疗效较好,毒副反应轻微。治疗后细胞免疫功能可以恢复到治疗前水平。

Objective To investigate the efficiency and toxicity of Gefitinib in the treatment of patients with advanced non-small cell lung cancer（NSCLC） and the characters of T lymphocyte subsets of the peripheral blood.Methods 60 patients confirmed by pathology or cytology with NSCLC have been received 250 mg oral doses of Gefitinib once a day.The frequencies of CD3＋,CD4＋,CD8＋ T lymphocyte in peripheral blood before and after treatment were determined by flow cytometry.Results Of all the 60 patients,with partial responses（PR） were 21 cases,with stable disease（SD） were 23 cases,with progressing disease（PD） were 16 cases,and the disease control rate（CR＋PR＋SD） was 73.3%.The drug-related adverse reactions were skin rash,dry skin,diarrhea,nausea and hepatic dysfunction.There was no significant difference of T lymphocyte subsets between the groups of before and after treatment（P0.05）.Conclusion Gefitinib is effective in treatment of patients with advanced NSCLC.It is well tolerated with minimal side-effects.The T lymphocyte immunological function could return to the level of before treatment.